UDK: 577.175.6:618.11]:618.177
Dukova I., Tofoski G., Naumovska R., Ilieva N., Tanturovski M., Atanasova Boshku A.
1University Clinic for Obstetrics and Gynecology, Skopje, Department for Infertility and Assisted Reproductive Techniques
| Tofoski Gligor | https://orcid.org/0009-0000-4704-7904 https://orcid.org/0000-0002-7181-455X |
| Ilieva Natasha | https://orcid.org/0000-0001-9783-6338 |
| Tanturovski Mile | https://orcid.org/0000-0002-9837-4806 |
| Atanasova Boshku Aleksandra | https://orcid.org/0000-0003-4049-8811 |
Abstract
Introduction: Ovarian reserve is a pivotal indicator of reproductive potential, assessed through biochemical and ultrasonographic markers, with age playing a dominant role in its decline.
Objectives: The study aimed to evaluate the correlations between anti-Müllerian hormone (AMH), follicle-stimulating hormone (FSH), and antral follicle count (AFC), and to assess the impact of age on these markers in infertile women.
Materials and methods:A cross-sectional study was conducted in 36 women aged 20–42 years. Serum AMH and FSH levels were measured, and AFC was assessed by transvaginal ultrasound. Data were analyzed using Spearman’s correlation and linear regression.
Results:Age proved to be a negative predictor of AMH and AFC (p < 0.05) and positively associated with FSH. A strong positive correlation was found between AMH and AFC (ρ = 0.866; p < 0.001), while FSH showed significant negative correlations with both parameters. Regression analysis demonstrated that AMH decreases by approximately 14% per year (B = –0.152; p = 0.020).
Conclusion:AMH emerges as the most sensitive and stable marker of ovarian reserve, and combined assessment of AMH and AFC offers the most reliable detection of diminished ovarian function in infertile women.
Keywords:anti-Müllerian hormone; antral follicle count; follicle-stimulating hormone; infertility; ovarian reserve.
References:
1. Tal R, Seifer DB. Ovarian reserve testing: a user’s guide. Am J Obstet Gynecol. 2017;217(2):129–40.
2. Hansen KR, Knowlton NS, Thyer AC, Charleston JS, Soules MR, Klein NA. A new model of reproductive aging: the decline in ovarian non-growing follicle number from birth to menopause. Hum Reprod. 2008;23(3):699–708.
3. Sharara FI, Scott RT, Seifer DB. The detection of diminished ovarian reserve in infertile women. Am J Obstet Gynecol. 1998;179(3):804–12.
4. Testing and interpreting measures of ovarian reserve: a committee opinion. Fertil Steril. 2015;103(3):e9–17.
5. Broer SL, Van Disseldorp J, Broeze KA, Dolleman M, Opmeer BC, Bossuyt P, et al. Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approach. Hum Reprod Update. 2013;19(1):26–36.
6. Kelsey TW, Wright P, Nelson SM, Anderson RA, Wallace WHB. A validated model of serum anti-Müllerian hormone from conception to menopause. PLoS One. 2011;6(7): e22024.
7. Bhowmik J, Fatima P, Banu J, Deeba F, Chowdhury S, Isharat S. Correlation between follicle stimulating hormone, anti-Müllerian hormone and antral follicle count with different age groups in infertile women. Chattagram Maa-O-Shishu Hosp Med Coll J. 2021;20(1):22–7.
8. Ferguson J, Hockley J, Rigsby P, Burns C. Establishment of a WHO reference reagent for anti-Müllerian hormone. Reprod Biol Endocrinol. 2020;18(1):86.
9. Johnson N, Bagrie E, Coomarasamy A, Bhattacharya S, Shelling A, Jessop S, et al. Ovarian reserve tests for predicting fertility outcomes for assisted reproductive technology: the International Systematic Collaboration of Ovarian Reserve Evaluation protocol for a systematic review. BJOG. 2006;113(12):1472–80.
10. Rose MP, Gaines Das RE, Balen AH. Definition and measurement of follicle stimulating hormone. Endocr Rev. 2000;21(1):5–22.
11. Cedars MI. Evaluation of female fertility—AMH and ovarian reserve testing. J Clin Endocrinol Metab. 2022;107(6):1510–9.
12. Moolhuijsen LME, Visser JA. Anti-Müllerian hormone and ovarian reserve: update on assessing ovarian function. J Clin Endocrinol Metab. 2020;105(11):3361–73.
13. Penzias A, Azziz R, Bendikson K, Falcone T, Hansen K, Hill M, et al. Testing and interpreting measures of ovarian reserve: a committee opinion. Fertil Steril. 2020;114(6):1151–7.
14. Coelho Neto MA, Ludwin A, Borrell A, Benacerraf B, Dewailly D, Da Silva Costa F, et al. Counting ovarian antral follicles by ultrasound: a practical guide. Ultrasound Obstet Gynecol. 2018;51(1):10–20.
15. Esteves SC, Yarali H, Vuong LN, Carvalho JF, Özbek İY, Polat M, et al. Cumulative delivery rate per aspiration IVF/ICSI cycle in POSEIDON patients: a real-world evidence study of 9073 patients. Hum Reprod. 2021;36(8):2157–69.
16. La Marca A, Spada E, Sighinolfi G, Argento C, Tirelli A, Giulini S, et al. Age-specific nomogram for the decline in antral follicle count throughout the reproductive period. Fertil Steril. 2011;95(2):684–8.
17. Barbakadze L, Kristesashvili J, Khonelidze N, Tsagareishvili G. The correlations of anti-Müllerian hormone, follicle-stimulating hormone and antral follicle count in different age groups of infertile women. Int J Fertil Steril. 2015;8(4):393–8.
18. Brodin T, Hadziosmanovic N, Berglund L, Olovsson M, Holte J. Antimüllerian hormone levels are strongly associated with live-birth rates after assisted reproduction. Acta ObstetGynecol Scand. 2015;94(11):1203–11.
19. Tehraninezhad ES, et al. The correlation of serum anti-Müllerian hormone with other ovarian reserve markers and ovarian response in infertile women. Int J Reprod Biomed. 2016;14(10):713–8.
20. Wani S, Wani R, Nisar S, Parveen S, Bhat R, Kadla S. Determination of ovarian reserve in different age groups of infertile women using serum AMH, FSH and antral follicle count as predictors. J Sci Soc. 2020;47(2):79–83.
21. Fleming R, Broekmans F, Calhaz-Jorge C, Driscoll G, de Vet A, Leask R, et al. Can anti-Müllerian hormone and antral follicle count predict ovarian response in IVF? A systematic review. Reprod Biomed Online. 2015;31(4):481–96.
22. Jain S, Jain N, Mathur R, Choudhary R, Shrivastava R. Correlation of anti-Müllerian hormone and antral follicle count with age in infertile women: A cross-sectional study. Int J ReprodContraceptObstetGynecol. 2021 ;10(3):1100–5.
23. Zhang B, Pei L, Song Y, Zhang L, Luo H, Sun J, et al. Age, anti-Müllerian hormone and antral follicle count in predicting ovarian reserve and reproductive potential in infertile women. Reprod Biol Endocrinol. 2019;17(1):115.
24. La Marca A, Sighinolfi G, Radi D, Argento C, Baraldi E, Artenisio AC, et al. Anti-Müllerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update. 2010;16(2):113–30.
25. Iliodromiti S, Nelson SM. Ovarian reserve markers: the role of AMH, AFC and FSH in reproductive medicine. Hum Reprod Update. 2015;21(5):698–710.
26. Salemi F, et al. Predictive value of anti-Müllerian hormone and antral follicle count for ovarian response: a systematic review and meta-analysis. Syst Rev. 2024;13(1):24.